<DOC>
	<DOCNO>NCT02760030</DOCNO>
	<brief_summary>This phase II clinical trial study well fulvestrant palbociclib work treat old patient breast cancer respond hormone treatment ( hormone responsive ) remove surgery . Estrogen cause growth estrogen-receptor-positive breast cancer cell . Hormone therapy use fulvestrant may fight estrogen-receptor-positive breast cancer block use estrogen tumor cell . Palbociclib may stop growth tumor cell block enzymes need cell growth . Giving fulvestrant together palbociclib may effective treatment hormone responsive breast cancer .</brief_summary>
	<brief_title>Fulvestrant Palbociclib Treating Older Patients With Hormone Responsive Breast Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine treatment failure-free survival ( TFFS ) rate one year combination therapy pure estrogen antagonist , fulvestrant cyclin-dependent kinase ( CDK ) inhibitor , palbociclib primary endocrine therapy patient 70 year old newly diagnose non-metastatic hormone receptor positive , human epidermal growth factor receptor 2 ( HER-2 ) negative breast cancer . SECONDARY OBJECTIVES : I . To determine 1- 2-year progression free survival . II . To determine safety toxicity combination population patient 70 year old . III . To determine whether longitudinal change geriatric assessment measure correlate tolerability regimen . OUTLINE : Patients receive fulvestrant intramuscularly ( IM ) day 1 15 . Patients also receive palbociclib orally ( PO ) daily ( QD ) day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 12 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Newly diagnose invasive , estrogen receptor ( ER ) and/or progesterone receptor ( PR ) positive , HER2 negative breast cancer ; ERand/or PRpositive breast cancer define &gt; 10 % stain immunohistochemistry Patients must vulnerable frail Balducci Criteria patient refuse breast surgery ; vulnerable patient define dependence instrumental activity daily live , well controlled comorbidities , early symptom geriatric syndrome ; frail patient define three comorbidities , dependence one activity daily live , clinically significant geriatric syndrome ; geriatric syndrome include : dementia , delirium , incontinence ( fecal and/or urinary ) , osteoporosis spontaneous fracture , polypharmacy , visual/hearing impairment , sarcopenia neglect abuse The patient 's refusal proceed curative breast surgery document surgeon 's medical oncologist 's note Absolute neutrophil count ( ANC ) &gt; 1000/uL Platelets &gt; 75,000/L Serum creatinine 1.5 X institutional upper limit normal ( ULN ) Total bilirubin &lt; 1.5 X ULN Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) 2.5 ULN Ability understand willingness sign write informed consent document Prior aromatase inhibitor therapy Evidence distant metastasis Psychiatric illness , would prevent patient give informed consent Patients receive strong inducer inhibitor cytochrome P450 3A4 ( CYP3A4 )</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>